期刊
CLINICAL LUNG CANCER
卷 24, 期 3, 页码 209-217出版社
CIG MEDIA GROUP, LP
DOI: 10.1016/j.cllc.2023.01.006
关键词
Liquid biopsy; Lung cancer; Early detection; Cancer screening; Cell free DNA
类别
Liquid biopsy (LB) is a clinically utilized tool to detect minute amounts of genetic material or protein shed by cancer cells, and can be used as a noninvasive precision oncology tool for cancer therapy guidance, tumor cell detection, and multi-cancer screening. It holds great promise in improving early lung cancer detection among all populations at risk.
Liquid biopsy (LB) is clinically utilized to detect minute amounts of genetic material or protein shed by cancer cells, most commonly cell free DNA (cfDNA), as a noninvasive precision oncology tool to assess genomic alterations to guide cancer therapy or to detect the persistence of tumor cells after therapy. LB is also being developed as a multi-cancer screening assay. The use of LB holds great promise as a tool to detect lung cancer early. Although lung cancer screening (LCS) with low-dose computed tomography (LDCT) substantially reduces lung cancer mortality in high-risk individuals, the ability of current LCS guidelines to reduce the public health burden of advanced lung cancer through early detection has been limited. LB may be an important tool to improve early lung cancer detection among all populations at risk for lung cancer. In this systematic review, we summarize the test characteristics, including sensitivity and specificity of individual tests, as they pertain to the detection of lung cancer. We also address critical questions in the use of liquid biopsy for early detection of lung cancer including: 1. How might liquid biopsy be used to detect lung cancer early; 2. How accurate is liquid biopsy in detecting lung cancer early; and 3. Does liquid biopsy perform as well in never and light-smokers compared with current and former smokers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据